Cardiovascular Risk Panels

Policy #  00398
Original Effective Date:  02/19/2014
Current Effective Date:  03/13/2023

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the “Company”), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

Note: Ultrasonographic Measurement of Carotid Intimal-Medial Thickness as an Assessment of Subclinical Atherosclerosis is addressed separately in medical policy 00251.

Services Are Considered Investigational
Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers cardiovascular (CV) risk panels, consisting of multiple individual biomarkers intended to assess cardiac risk (other than simple lipid panels), to be investigative.* (See Note)

Note:
A simple lipid panel is generally composed of the following lipid measures:
- Low-density lipoprotein (LDL) cholesterol
- High-density lipoprotein (HDL) cholesterol
- Triglycerides
- Total cholesterol

Certain calculated ratios, such as the total/high-density lipoprotein (HDL) cholesterol may also be reported as part of a simple lipid panel.

Other types of lipid testing, i.e., apolipoproteins, lipid particle number or particle size, lipoprotein (a), etc., are not considered to be components of a simple lipid profile.

This policy does not address the use of panels of biomarkers in the diagnosis of acute myocardial infarction.
Cardiovascular Risk Panels

Policy # 00398
Original Effective Date: 02/19/2014
Current Effective Date: 03/13/2023

**Background/Overview**

**Cardiovascular Disease**
Cardiovascular disease (CVD) remains the single largest cause of morbidity and mortality in the developed world. Mortality from CVD has accounted for 1 in 4 deaths in the United States, and there are numerous socio-economic factors that affect CVD mortality rates. Lower-income, race, age, and behavioral factors all have a significant impact on health outcome disparities associated with CVD.

As a result, accurate prediction of CVD risk is a component of medical care that has the potential to focus on and direct preventive and diagnostic activities. Current methods of risk prediction in use in general clinical care are not highly accurate and, as a result, there is a potential unmet need for improved risk prediction instruments.

**Risk Assessment**
Components of CVD risk include family history, cigarette smoking, hypertension, and lifestyle factors such as diet and exercise. Also, numerous laboratory tests have been associated with CVD risk, most prominently lipids such as low-density lipoprotein (LDL) and high-density lipoprotein (HDL). These clinical and lipid factors are often combined into simple risk prediction instruments, such as the Framingham Risk Score. The Framingham Risk Score provides an estimate of the 10-year risk for developing cardiac disease and is currently used in clinical care to determine the aggressiveness of risk factor intervention, such as the decision to treat hyperlipidemia with statins. Many additional biomarkers, genetic factors, and radiologic measures have been associated with an increased risk of CVD. Over 100 emerging risk factors have been proposed as useful for refining estimates of CVD risk. Some general categories of these potential risk factors are as follows:

- **Lipid markers.** In addition to LDL and HDL, other lipid markers may have predictive ability, including the apolipoproteins, lipoprotein (a) (Lp[a]), lipid subfractions, and/or other measures.
- **Inflammatory markers.** Many measures of inflammation have been linked to the likelihood of CVD. High-sensitivity C-reactive protein (hs-CRP) is an example of an inflammatory marker; others include fibrinogen, interleukins, and tumor necrosis factor.
- **Metabolic syndrome biomarkers.** Measures associated with metabolic syndromes, such as specific dyslipidemic profiles or serum insulin levels, have been associated with an increased risk of CVD.
Cardiovascular Risk Panels

Policy # 00398
Original Effective Date: 02/19/2014
Current Effective Date: 03/13/2023

- **Genetic markers.** A number of variants associated with increased thrombosis risk, such as the 5,10-methylene tetrahydrofolate reductase (MTHFR) variant or the prothrombin gene variants, have been associated with increased CVD risk. Also, numerous single nucleotide variants have been associated with CVD in large genome-wide studies.

Risk Panel Testing
Cardiovascular disease risk panels may contain measures from 1 or all of the previous categories and may include other measures not previously listed such as radiologic markers (carotid medial thickness, coronary artery calcium score). Some CVD risk panels are relatively limited, including a few markers in addition to standard lipids. Others include a wide variety of potential risk factors from a number of different categories, often including both genetic and nongenetic risk factors. Other panels are composed entirely of genetic markers.

Some examples of commercially available CVD risk panels are as follows:
- **CV Health Plus Genomics™ Panel (Genova Diagnostics):** apolipoprotein (apo) E; prothrombin; factor V Leiden; fibrinogen; HDL; HDL size; HDL particle number; homocysteine; LDL; LDL size; LDL particle number; Lp(a); lipoprotein-associated phospholipase A2 (Lp-PLA2); MTHFR gene; triglycerides; very-low-density lipoprotein (VLDL); VLDL size; vitamin D; hs-CRP.
- **CV Health Plus™ Panel (Genova Diagnostics):** fibrinogen; HDL; HDL size; HDL particle number; homocysteine; LDL; LDL size; LDL particle number; lipid panel; Lp(a); Lp-PLA2; triglycerides; VLDL; VLDL size; vitamin D; hs-CRP.
- **CVD Inflammatory Profile (Cleveland HeartLab):** hs-CRP, urinary microalbumin, myeloperoxidase, Lp-PLA2, F2 isoprostanes.
- **Applied Genetics Cardiac Panel:** genetic variants associated with coronary artery disease: cytochrome p450 variants associated with the metabolism of clopidogrel, ticagrelor, warfarin, b-blockers, rivaroxaban, prasugrel (2C19, 2C9/VKORC1, 2D6, 3A4/3A5), factor V Leiden, prothrombin gene, MTHFR gene, APOE gene.
- **Genetiks Genetic Diagnosis and Research Center Cardiovascular Risk Panel:** factor V Leiden, factor V R2, prothrombin gene, factor XIII, fibrinogen-455, plasminogen activator inhibitor-1, platelet glycoprotein (GP) IIIA variant human platelet antigen (HPA)-1 (PLA1/2), MTHFR gene, angiotensin-converting enzyme insertion/deletion, apo B, apo E.
Cardiovascular Risk Panels

Policy # 00398
Original Effective Date: 02/19/2014
Current Effective Date: 03/13/2023

In addition to panels that are specifically focused on CVD risk, a number of commercially available panels include markers associated with cardiovascular health, along with a range of other markers that have been associated with inflammation, thyroid disorders and other hormonal deficiencies, and other disorders. An example of these panels is:

- **WellnessFX Premium (WellnessFX):** total cholesterol, HDL, LDL, triglycerides, apo AI, apo B, Lp(a), Lp-PLA2, omega-3 fatty acids, free fatty acids, lipid particle numbers, lipid particle sizes, blood urea nitrogen/creatinine, aspartate aminotransferase and alanine aminotransferase, total bilirubin, albumin, total protein, dehydroepiandrosterone, free testosterone, total testosterone, estradiol, sex hormone binding globulin, cortisol, insulin-like growth factor 1, insulin, glucose, hemoglobin A1c, total T4, T3 uptake, free T4 index, thyroid-stimulating hormone, total T3, free T3, reverse T3, free T4, hs-CRP, fibrinogen, homocysteine, complete blood count with differential, calcium, electrolytes, bicarbonate, ferritin, total iron-binding capacity, vitamin B12, red blood cell magnesium, 25-hydroxy vitamin D, progesterone, follicle-stimulating hormone, luteinizing hormone.

**FDA or Other Governmental Regulatory Approval**

**U.S. Food and Drug Administration (FDA)**

Multiple assay methods for cardiac risk marker components, such as lipid panels and other biochemical assays, have been cleared for marketing by the U.S. FDA through the 510(k) process.

Other components of testing panels are laboratory-developed tests. Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments. Laboratories that offer laboratory-developed tests must be licensed by the Clinical Laboratory Improvement Amendments for high-complexity testing. To date, the FDA has chosen not to require any regulatory review of this test.

**Rationale/Source**

This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. Food and Drug Administration approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.
Cardiovascular Risk Panels

Policy # 00398
Original Effective Date: 02/19/2014
Current Effective Date: 03/13/2023

Cardiovascular risk panels refer to different combinations of cardiac markers that are intended to evaluate the risk of CVD. There are numerous commercially available risk panels that include different combinations of lipids, noncardiac biomarkers, measures of inflammation, metabolic parameters, and/or genetic markers. Risk panels report the results of multiple individual tests, as distinguished from quantitative risk scores that combine the results of multiple markers into a single score.

For individuals who have risk factors for CVD who receive CVD risk panels, the evidence includes multiple cohorts and case-control studies and systematic reviews of these studies. Relevant outcomes are test validity, other test performance measures, change in disease status, and morbid events. The available evidence from cohort and case-control studies indicates that many of the individual risk factors included in CVD risk panels are associated with increased risk of CVD. However, it is not clear how the results of individual risk factors impact management changes, so it is also uncertain how the panels will impact management decisions. Given the lack of evidence for the clinical utility of any individual risk factor beyond simple lipid measures, it is unlikely that the use of CVD risk panels improves outcomes. Studies that have evaluated the clinical validity of panels of multiple markers have not assessed management changes that would occur as a result of testing or demonstrated improvements in outcomes. The evidence is insufficient to determine that the technology results in an improvement in the net health outcomes.

Supplemental Information

Practice Guidelines and Position Statements
Guidelines or position statements will be considered for inclusion in ‘Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

American College of Cardiology/American Heart Association
In 2013, the American College of Cardiology and the American Heart Association issued joint guidelines for the assessment of cardiovascular disease risk. These guidelines recommended that age- and sex-specific pooled cohort equations, which included total cholesterol and high-density lipoprotein to predict the 10-year risk of a first hard atherosclerotic cardiovascular disease event, be
Cardiovascular Risk Panels

Policy # 00398
Original Effective Date: 02/19/2014
Current Effective Date: 03/13/2023

used in non-Hispanic blacks and non-Hispanic whites between 40 and 79 years of age (American Heart Association/American College of Cardiology class of recommendation I, American Heart Association/American College of Cardiology level of evidence B). Regarding newer risk markers after quantitative risk assessment, the guidelines stated the following: “If, after quantitative risk assessment, a risk-based treatment decision is uncertain, assessment of ≥1 of the following: family history, hs-CRP [high-sensitivity C-reactive protein], CAC [coronary artery calcium] score, or ABI [ankle-brachial index] may be considered to inform treatment decision-making” (class of recommendation IIb, level of evidence B). The guidelines did not recommend other novel cardiac risk factors or panels of cardiac risk factors.

In 2019, the American College of Cardiology/American Heart Association issued a special report on the use of risk assessment tools to guide decision-making in the primary prevention of atherosclerotic CVD. Although the report did not recommend specific novel cardiac risk factors or panels of cardiac risk factors, it discusses features of current US-based CV risk assessment tools including the Reynolds Risk Score, which includes hs-CRP level as one of its variables, mentions risk-enhancing factors for a clinician-patient risk discussion including elevated hs-CRP, lipoprotein(a), and apolipoprotein B levels, and the use of CAC measurement to reclassify CVD risk.

European Society of Cardiology/European Atherosclerosis Society
In 2019, the European Society of Cardiology and European Atherosclerosis Society published a guideline for the management of dyslipidemias: lipid modification to reduce CV risk. This guideline contains updated recommendations for lipid analyses for CV disease risk estimation. Beyond traditional lipid markers (ie, total cholesterol, HDL, LDL, and triglycerides), the guideline recommends non-HDL-C "for risk assessment, particularly in people with high triglyceride levels, diabetes mellitus, obesity, or very low LDL-C levels" [Class I recommendation; Level C evidence (consensus of opinion of the experts and/or small studies, retrospective studies, registries)]. Apolipoprotein B is recommended "for risk assessment, particularly in people with high triglyceride levels, diabetes mellitus, obesity, metabolic syndrome, or very low LDL-C levels. It can be used as an alternative to LDL-C, if available, as the primary measurement for screening, diagnosis, and management, and may be preferred over non-HDL-C in people with high triglyceride levels, diabetes mellitus, obesity, or very low LDL-C levels" [Class I recommendation; Level C evidence]. Additionally, the guideline states that lipoprotein(a) measurement "should be considered at least once in each adult person's lifetime to identify those with very high inherited lipoprotein(a) levels > 180 mg/dL who may have a lifetime risk of atherosclerotic CVD equivalent to the risk associated
Cardiovascular Risk Panels

Policy # 00398
Original Effective Date: 02/19/2014
Current Effective Date: 03/13/2023

with heterozygous familial hypercholesterolemia" and "should be considered in selected patients with a family history of premature CVD, and for reclassification in people who are borderline between moderate and high-risk" [Class I:a recommendation; Level C evidence].

In 2021, the European Society of Cardiology published a guideline on CVD prevention, however, the guideline did not recommend specific novel cardiac risk factors or panels of cardiac risk factors for the assessment of CVD risk. The guideline states that "main causal and modifiable ASCVD [atherosclerotic cardiovascular disease] risk factors are blood apolipoprotein-B-containing lipoproteins, high BP [blood pressure], cigarette smoking, and DM [diabetes mellitus]". The guideline also states that the ankle brachial index may be considered as a risk modifier in CVD risk assessment but the "routine collection of other potential modifiers, such as genetic risk scores, circulating or urinary biomarkers, or vascular tests or imaging methods (other than CAC scoring or carotid ultrasound for plaque determination), is not recommended."

U.S. Preventive Services Task Force Recommendations
No recommendations specific to the use of cardiovascular disease risk panels were identified. In 2018, the U.S. Preventive Services Task Force updated its recommendation on the use of nontraditional risk factors in CVD risk assessment:

“The USPSTF concludes that there are insufficient adequately powered clinical trials evaluating the incremental effect of the ankle-brachial index (ABI), high-sensitivity C-reactive protein (hsCRP) level, or coronary artery calcium (CAC) score in risk assessment and initiation of preventive therapy. Furthermore, the clinical meaning of improvements in measures of calibration, discrimination, and reclassification risk prediction studies is uncertain.”

Medicare National Coverage
There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

Ongoing and Unpublished Clinical Trials
Some currently unpublished trials that might influence this review are listed in Table 1.
Cardiovascular Risk Panels

Policy # 00398
Original Effective Date: 02/19/2014
Current Effective Date: 03/13/2023

Table 1. Summary of Key Trials

<table>
<thead>
<tr>
<th>NCT No.</th>
<th>Trial Name</th>
<th>Planned Enrollment</th>
<th>Completion Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unpublished</td>
<td>A Pilot Study to Evaluate the Utility of the SomaLogic CVD Secondary Risk Panel as a Tool to Stratify Cardiovascular Risk</td>
<td>244</td>
<td>Oct 2020</td>
</tr>
<tr>
<td>NCT03599531</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

NCT: national clinical trial.

References
Cardiovascular Risk Panels

Policy # 00398
Original Effective Date: 02/19/2014
Current Effective Date: 03/13/2023


Cardiovascular Risk Panels

Policy #  00398
Original Effective Date:  02/19/2014
Current Effective Date:  03/13/2023


©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Cardiovascular Risk Panels

Policy # 00398
Original Effective Date: 02/19/2014
Current Effective Date: 03/13/2023


Policy History
Original Effective Date: 02/19/2014
Current Effective Date: 03/13/2023
02/06/2014 Medical Policy Committee review
02/19/2014 Medical Policy Implementation Committee approval. New policy.
02/05/2015 Medical Policy Committee review
02/18/2015 Medical Policy Implementation Committee approval. No coverage changes.
08/03/2015 Coding update: ICD10 Diagnosis code section added; ICD9 Procedure code section removed.
02/04/2016 Medical Policy Committee review
02/17/2016 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
01/01/2017 Coding update: Removing ICD-9 Diagnosis Codes
02/02/2017 Medical Policy Committee review
02/15/2017 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
02/01/2018 Medical Policy Committee review
02/21/2018 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
02/07/2019 Medical Policy Committee review
02/20/2019 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
02/06/2020 Medical Policy Committee review
02/12/2020 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
02/04/2021 Medical Policy Committee review
02/10/2021 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
02/03/2022 Medical Policy Committee review

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Cardiovascular Risk Panels

Policy # 00398
Original Effective Date: 02/19/2014
Current Effective Date: 03/13/2023

02/09/2022 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
02/22/2022 Coding update
02/02/2023 Medical Policy Committee review
02/08/2023 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
08/09/2023 Coding update

Next Scheduled Review Date: 02/2024

Coding
The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®), copyright 2022 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

©2023 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Cardiovascular Risk Panels

Policy # 00398  
Original Effective Date: 02/19/2014  
Current Effective Date: 03/13/2023

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

<table>
<thead>
<tr>
<th>Code Type</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>81401, 81599</td>
</tr>
<tr>
<td></td>
<td>Delete codes effective 4/1/2022: 83722, 0052U, 0119U</td>
</tr>
<tr>
<td></td>
<td>Add code effective 07/01/2023: 0401U</td>
</tr>
<tr>
<td>HCPCS</td>
<td>No codes</td>
</tr>
<tr>
<td>ICD-10 Diagnosis</td>
<td>All related diagnoses</td>
</tr>
</tbody>
</table>

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or

B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:
   1. Consultation with technology evaluation center(s);
   2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
   3. Reference to federal regulations.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: If the Patient’s health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.
Cardiovascular Risk Panels

Policy #  00398
Original Effective Date:  02/19/2014
Current Effective Date:  03/13/2023

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.